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Tissue factor pathway inhibitor-2 (TFPI-2) has previously been characterized as an
endogenous anticoagulant. TFPI-2 is expressed in the vast majority of cells, mainly
secreted into the extracellular matrix. Recently we reported that EDC34, a C-terminal
peptide derived from TFPI-2, exerts a broad antimicrobial activity. In the present
study, we describe a previously unknown antimicrobial mode of action for the human
TFPI-2 C-terminal peptide EDC34, mediated via binding to immunoglobulins of the
classes IgG, IgA, IgE, and IgM. In particular the interaction of EDC34 with the Fc
part of IgG is of importance since this boosts interaction between the immunoglobulin
and complement factor C1q. Moreover, we find that the binding increases the C1q
engagement of the antigen-antibody interaction, leading to enhanced activation of the
classical complement pathway during bacterial infection. In experimental murine models
of infection and endotoxin challenge, we show that TFPI-2 is up-regulated in several
organs, including the lung. Correspondingly, TFPI-2−/− mice are more susceptible to
pulmonary Pseudomonas aeruginosa bacterial infection. No anti-coagulant role of TFPI-2
was observed in these models in vivo. Furthermore, in vivo, the mouse TFPI-2-derived
C-terminal peptide VKG24, a homolog to human EDC34 is protective against systemic
Escherichia coli bacterial infection. Moreover, in sputum from cystic fibrosis patients
TFPI-2 C-terminal fragments are generated and found associated with immunoglobulins.
Together our data describe a previously unknown host defense mechanism and
therapeutic importance of TFPI-2 against invading Gram-negative bacterial pathogens.
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INTRODUCTION
The exploration of immuno-modulating proteins and peptides has attracted a significant interest
within the past years (1, 2). To this end, techniques such as phage display (3, 4) and peptide array
technologies (5) had been developed that allow the detection of potential interactions between
these peptides and their potential interaction partners. Notably, the mammalian immune system
is in the focus of such analyses as there are many reports showing that it can by modulated by a
variety of exogenous peptides. During million years of evolution the mammalian immune system
has evolved into a complex and self-regulating network comprised by many components that
orchestrate with each other to ascertain maximum protection for the host (6). However, some
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microorganisms have succeeded to manipulate the host response
by deceiving the immune defense system and crossing the
firewall of protection. Though bacteria can very easily adapt
to new hostile environments, there have been only be a few
examples showing that they can also counteract the activity
of antimicrobial peptides (AMPs). Thus, AMPs demonstrate
a significant potential as novel therapeutic agents. Many
researchers have therefore extensively investigated different
classes of endogenous peptides derived for instance from
mammalian neutrophils, i.e., cathelicidins and defensins (7).
AMPs are found in all life forms including bacteria, fungi, plants,
invertebrates, and vertebrates (8). They are essential components
of the innate immune system (9), as they help to ensure the
maximumprotection for the host against pathogens and invading
microbes (10, 11). In addition to their involvement in direct
extermination of various microorganisms, AMPs can mediate
diverse immunomodulatory responses (12, 13). These include
stimulation of macrophages, lymphocytes and neutrophils (9),
induction of angiogenesis (14), triggering in wound healing (15),
and neutralizing lipopolysaccharide endotoxins derived from
Gram-negative bacteria (16).
During the past decade there have been several findings on
HDPs generated from proteins involved in coagulation including
thrombin (17–19), HCAII (20), TFPI-1 (21) among others. There
are also host derived peptides generated through proteolytic
cleavage by bacterial proteases, as recently discovered in the case
of Pseudomonas aeruginosa (22). P. aeruginosa infect by several
additional strategies, targeting matrix remodeling, impressively
proven by the TIMP-1−/− mice and their resistance to infection
by this particular pathogen. Importantly, the protective role
in the case of TIMP1−/− mice was accompanied by increased
inflammatory and complement-dependent immune regulation
(23). Structurally related, to an extent of approximately 50% on
both nucleotide and amino acid level to TFPI-1, is it’s sister
protein TFPI-2 also called Matrix Serine Proteinase Inhibitor
(MSPI) and Placental Protein 5 (PP5) (24–26). TFPI-2 exerts not
only antimicrobial properties against Gram-negative infection
(27)—the protein is also present in skin and the C-terminal
region have shown to be up-regulated at the edges of both acute
and chronic wounds (28). Importantly, TFPI-2 has previously
been shown to inhibit several MMPs, both indirectly and
through protein-protein interactions. The importance of the
MMP inhibitory capabilities of TFPI-2 during dysfunctional
matrix turnover as in arthritis, atherosclerosis and cancer are
getting increased attention (29–31). The possibility to modify
local concentrations of MMPs and their inhibitors has a large
therapeutic potential in many immunopathologies, including
those seen during infections (32).
Previous studies have shown that complement activation can
be amplified by targeting certain proteins such as complement
factor C3 (33). Elvington et al. for instance described in 2012 a
method showing that complement activation can be used as
cancer therapy. To this end the authors employed a fusion
protein of a complement receptor and an IgG Fc fragment to
improve the outcome of mAb therapy in a murine metastatic
cancer model (33). In another study, we found that EDC34,
a peptide derived from human TFPI-2, enhances the binding
of C1q to bacterial surfaces. Moreover EDC34 is able to up
regulate the antimicrobial activity of C3a, which in turn can
cause amplification of the classical complement system pathway
(27). These findings further reveal that EDC34 has a significant
capacity to eradicate in particular Gram-negative bacteria in
vivo (27, 28). Based on these results, we therefore decided to
investigate the mode of action of C-terminal TFPI-2 region
under infectious disease conditions. Our finding demonstrates
that EDC34 is capable of binding to immunoglobulins (IgA, IgG,
IgE, and IgM), by specifically engaging the Fc region of IgG.
These finding were confirmed in in vivo infection studies using
a peptide derived from the C-terminal part of murine TFPI-
2 and were further underlined by employing TFPI-2−/− mice
experiments. Together our results suggest an important role of
the C-terminal TFPI-2 region in boosting the host defense against
invading pathogens.
MATERIALS AND METHODS
Peptides and Microorganisms
The peptides listed in Table 1 were synthesized by Biopeptide
Co., San Diego, CA. The purity (>95%) of these peptides was
confirmed by mass spectral analysis (MALDI-ToF Voyager). The
bacterial isolate Escherichia coli ATCC 25922 was obtained from
the American Type Culture Collection and Xen41 was obtained
form PerkinElmer. Mouse VKG24 peptide was synthesized by
Ontores (Shanghai, China).
Radial Diffusion Assay (RDA)
Escherichia coli was grown to mid-logarithmic phase in 10ml
(3% w/v) of trypticase soy broth (TSB). Bacteria were washed
and re-suspended in 10mM Tris, pH 7.4 to obtain a dilution
of 1% of bacterial suspension (1–2 × 109 colony forming units
cfu/ml). Subsequently, 6.6 µl of bacteria were added to 15ml of
melted underlay agarose gel consisting of 0.03% (w/v) TSB, 1%
(w/v) low electroendosmosis type (EEO) agarose and 0.02% (v/v)
Tween 20 (Sigma) with or without 150mM NaCl. The mixture
was poured to a 144mm sterile petri dish and left to solidify. After
that, 4mm diameter wells were punctured and 100µM peptides
were added to each well. Plates were incubated for 3 h at 37◦C
TABLE 1 | C-terminal human TFPI-2 derived peptides.
TFPI-2 derived peptides
EDC34: EDCKRACAKALKKKKKMPKLRFASRIRKIRKKQF
AKA27: ——-AKALKKKKKMPKLRFASRIRKIRKKQF
AKA27 (S1): ——-AKALSSSSSMPKLRFASRIRKIRKKQF
AKA27 (S2): ——-AKALKKKKKMPKLRFASSISSISSSQF
AKA27 (S3): ——-AKALSSSSSMPKLRFASSISSISSSQF
LKK22: LKKKKKMPKLRFASRIRKIRKK
AKA15: AKALKKKKKMPKLRF
LRF15: LRFASRIRKIRKKQF
DAA14: DAAQEPTGNNAET
The colored letters indicate a substitution of either lysine or arginine into serine residue.
DAA14 is derived from the N-terminal region of human TFPI-2.
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and then covered by adding 15ml of over-lay gel consisting of
6% TSB and 1% Low-EEO agarose in Millipore water. After 16–
24 h of incubation at 37◦C, the peptides diffusion around each
well formed the zone of inhibition, which corresponded to the
peptide’s antimicrobial activity.
Viable Count Assay (VCA)
Escherichia coli bacteria were grown to mid-logarithmic phase
in 10ml of (3% w/v) Todd-Hewitt (TH), bacteria were washed
and diluted in buffer 10mM Tris, pH 7.4, containing 150mM
NaCl, either alone or with the presence of human 20% citrate
plasma, lepirudin, heparin, EDTA plasma, or serum. 1–2 × 106
cfu/ml bacteria were incubated in a total volume of 50µl with the
indicated concentrations of C-terminal TFPI-2 derived peptides
for 2 h at 37◦C. Alternatively, 1–2× 106 cfu/ml of E. coli bacteria
in the presence or absence of EDC34were incubated either in PBS
alone or PBS supplemented with 25% of human citrated plasma,
immunoglobulins depleted citrated plasma, or immunoglobulins
depleted citrated plasma supplemented with 10 µg of IgG/µl,
for 2 h at 37◦C. Serial of dilutions of the reaction mixture were
plated on TH agar plates, followed by the incubation at 37◦C
overnight. The number of colony forming units was determined
as a percentage to control sample.
SDS PAGE and Immunoblotting
Three µg of IgG or IgA or IgE or IgM were incubated in 20 µl of
buffer (10mM Tris, 150mM NaCl, pH 7.4), either alone or with
0.5 µg (6µM) of EDC34 for 1 h at 37◦C. Samples were diluted in
SDS buffer and analyzed under non-reducing conditions by SDS-
PAGE on Criterion TGX Any kD Gel (BioRad). Alternatively,
EDC34 (6µM) was incubated either alone or in PBS containing
20% serum, citrate, lepirudin, EDTA plasma at different time
points (15, 30, 60, and 120min). Samples were analyzed under
non-reducing conditions.
Six µM of EDC34 was either incubated alone or with IgGs
in 10mM Tris, 150mM NaCl, pH 7.4 buffer, under similar
concentrations for 15, 30, 60, 120min or 24 h at 37◦C. In another
experiment, 6µM of EDC34 was pre-incubated with 50µM
of TCEP (tris(2-carboxyethyl)phosphine) for 30min at room
temperature before IgG (6µM) was added. The mixture was
further incubated for 24 h at 37◦C. In another experiment, 6µM
of IgG or Fab-IgG or Fc-IgG were incubated with or without
6µM of EDC34 in 10mM Tris, 150mM NaCl, pH 7.4 buffer
for 30min at 37◦C. Proteins and peptides were transferred to
nitrocellulose membranes (Hybond-C), blocked by 5% (w/v)
skimmed milk, washed and incubated with rabbit polyclonal
antibodies to CAK27 or rabbit polyclonal antibodies to IgG
(or 1:1,000) (Dako) or rabbit polyclonal antibodies to C1q (or
1:1,000) (Dako). Polyclonal swine anti-rabbit immunoglobulin
secondary HRP antibody (1:1,000) was used for detection and an
enhanced chemiluminescent Substrate (LumiGLO) developing
system (Upstate cell signaling solutions).
Pull Down Assay
In a total volume of 500 µl PBS buffer, 2µM of EDC34, and
8µM of IgG were incubated for 24 h at 37◦C. Subsequently, E.
coli bacteria (1–2× 106 cfu/ml) were added, and then themixture
was incubated for additional 1 h. In a parallel experiment, the
bacteria in the presence of absence of EDC34 were incubated for
30min at 37◦C before IgG was added for 1 h at 37◦C. Samples
were then centrifuged, bacterial pellets were washed twice with
PBS and then re-suspended in 360 µl of 0.1M glycine, pH 2.0
to elute the bound proteins. The pH of the eluted material was
raised to 7.5 with 1M Tris. Thereafter, 100 µl of 100% TCA were
added to precipitate the eluted proteins followed by incubation
for 10min at−20◦ C followed by a centrifugation step for 20min
at 15,000 × g (4◦C). The pellets were washed with acetone and
left to air dry before they were dissolved in loading dye and
analyzed under non-reducing conditions by SDS-PAGE, followed
by Western blot analysis.
Immunoglobulin Depletion
The experiments were performed according to the manufacture’s
instructions. Briefly, total albumins and (>98%) and
immunoglobulins (IgG, IgA, IgM, IgE, and IgD >99%)
were depleted in human citrated plasma using PureProteomeTM
Human Albumin/Immunoglobulin Depletion Kit (Millipore).
Surface Plasmon Resonance
IgG was immobilized (15µg/mL) on a CM5 sensor chip via
amine coupling in a 10mM sodium acetate buffer (pH 4). A
blank immobilization was performed in flow cell one. EDC34 was
injected at different concentrations (25–400 nM) at a flow rate of
30 µl/min and a temperature of 25◦C over the flow cells using a
running buffer containing 10mm Hepes, 150mm NaCl, 0.005%
surfactant P20, and 3.4mM EDTA (pH 7.5). Regeneration of
the sensor surface was conducted in 0.5M sodium chloride. The
analysis was performed using a Biacore X100 instrument (GE
Healthcare, Uppsala, Sweden) and the data was fitted using a 1:1
binding model.
Generation of TFPI-2 Knock Out Mice
TFPI-2 conditional knockout mice were generated by Deltagen
(San Mateo, CA, USA). Male chimeric mice were mated with
C57BL/6J female mice, and F1 heterozygous mice TFPI-2+/−,
were mated with each other to yield complete knockout mice
TFPI-2−/− (Data sheet 1). All experiments were performed
facilitating female and male mice at the age between of 6 and
8 weeks according to protocols approved by the Animal Ethics
Committee, Lund, Sweden. Animals were housed under standard
conditions of light and temperature and had free access to
standard laboratory chow and water.
E. coli Mouse Infection Model
Escherichia coli ATCC 25922 bacteria were grown to reach mid-
exponential phase (OD620 ∼0.4), washed twice in PBS and then
diluted in PBS. Balb/c mice (7 weeks, n = 6 per group) were
intraperitoneally (i. p) injected with 100 µl (8–8.5 × 108 cfu/ml)
of E. coli. One hour after bacterial injection, VKG24 (500 µg
per mouse) or PBS buffer alone were injected (i. p). Mice were
sacrificed after 8 h post-infection and cfu were evaluated in blood,
lung, spleen, kidney and liver.
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Reactive Oxygen Species (ROS)
Production Assay
AIN-93M-Purified diet (ENVIGO) was provided for 1 week to
mice, after 8 h post-infection mice were anesthetized and L-021
dye 25mg per kg (Wako) was injected subcutaneously (s. c.),
after 10–12min of incubation. Reactive oxygen species (ROS)
production was detected by measuring fluorescence in radiance
(p/sec) for control and treated mice using IVIS R© Spectrum
(version 4.4, Caliper Life Sciences). Imaging was performed in
groups of 2 and 3 animals at a time.
In vivo TFPI-2 Expression
Escherichia coli ATCC 25922 bacteria were grown to mid-
exponential phase (OD620∼0.5), harvested, washed in PBS
and diluted in the same buffer to 3–4 × 108 cfu/ml.
Two hundred microliter of the bacterial suspension was
injected intraperitoneally (i. p) into C57BL/6 mice. In another
experiment, C57BL/6 mice were i. p. injected with 8 mg/kg of
E. coli O111:B4 LPS (Sigma). In both cases, for evaluation of
TFPI-2 expression, mice were sacrificed 0, 1, 2, 4, 6, and 12 h
post-infection, and lung, brain, spleen, liver, kidney, small, and
large intestine were harvested in trizol reagent. Before isolating
RNA all organs were stored at−80◦C.
P. aeruginosa Mouse Infection Model
Animals were housed under standard conditions of light
and temperature, with access to chow and water ad libitum.
Pseudomonas aeruginosa Xen41 bacteria were grown to
logarithmic phase (OD620∼0.5), harvested, washed in PBS, pH
7.4 and diluted in PBS to either 3–4 × 108 cfu/ml, and kept on
ice until injection. Fifty microliter of the bacterial suspension
was administered intra nasally into mice. The survival data were
obtained by following the animals daily up to 7 days monitoring.
Mice reaching the pre-defined endpoint criteria were sacrificed
and counted as non-survivors. For bacterial dissemination, mice
were sacrificed after 12 h and cfu were determined in BALF and
lung.
Cytokine Assay
The cytokines IL-6, IL-10, MCP-1, IFN-γ, TNF-α were measured
in plasma and BAL fluid from mice intra-nasally infected with
P. aeruginosa using the Cytometric bead array (CBA) Mouse
Inflammation Kit # 552364 (Becton Dickinson AB) according to
themanufacturer’s instructions on a FACSCalibur flow cytometer
(Becton Dickinson AB). All plasma samples were stored at
−80◦C before the analysis.
Statistical Analyses
Values are shown as mean with SEM. For statistical evaluation
of two experimental groups, one-way with Tukey’s multiple
comparisons post-test was used and for comparison of survival
curves the Mantel-Cox’s test. Viable count and radial diffusion
assay data are presented as mean with SD. All statistical
evaluations were performed using the GraphPad Prism software
7.0 with ∗p < 0.05, ∗∗p < 0.01, ∗∗∗ < 0.001, ∗∗∗∗p < 0.0001, and
ns, not significant.
RESULTS
Functional Characterization of EDC34
Under ex vivo Conditions
Many factors including pH, salt concentrations, or interacting
proteins, have been described to alter the antimicrobial activity
of a number of AMPs (30). To test whether these parameters
have an effect on EDC34, the antimicrobial activity of the
peptide was analyzed under five different plasma conditions
(including human serum, citrate plasma, lepirudin-, heparin-,
and EDTA-plasma, respectively). As shown in Figure 1A, EDC34
is able to completely eradicate the bacteria in citrate plasma
(CP), while its antimicrobial activity is decreased in lepirudin
or EDTA plasma as well as in serum. When the experiment
was performed with heparin plasma the bactericidal effect of
EDC34 was significantly blocked resulting in the survival rates
rate exceeding 80%. The latter findings were expected since
also many other heparin-binding AMPs lose their antimicrobial
activity in the presence of heparin (34). Peptide stability can be
influenced by many different conditions including proteolytic
degradation. To test whether EDC34 is resistant to proteolysis,
the peptide was incubated with three different anticoagulant
plasmas as well as with serum. Samples were collected after
different time points and subjected to western blot analysis
probing with an antibody against the C-terminal part of
TFPI-2. When incubated with serum, EDC34 was completely
degraded after an incubation time of 15min. However, when
the experiment was performed in citrate, lepirudin, or EDTA-
plasma, we noticed that EDC34 immediately formed a complex
with a protein with an apparent molecular weight of about 180
kDa (Figure 1B). In this complex EDC34 seemed to be more
stable as it started to degrade in EDTA plasma after 60min
and remained intact for more than 2 h in citrate and lepirudin
plasma.
EDC34 Interacts With Immunoglobulins
IgG is one of most abundant proteins in plasma and has
a molecular weight in the range of 180 kDa. Thus, we
hypothesized that EDC34 can interact with IgG or even
with other immunoglobulins. In order to test this hypothesis,
EDC34 was incubated with different classes of human purified
immunoglobulins, i.e., IgA, IgG, IgE, and IgM and binding
was tested by immunoblotting. Our results show that EDC34
avidly binds to all immunoglobulins tested (Figure 1C). When
the interaction of the peptide with IgG was studied over time,
we found that it was entirely absorbed after a 24 h incubation
(Figure 1D). EDC34 contains two cysteine amino acids and to
exclude that the interaction between EDC34 and IgG is the result
of unspecifically newly formed disulphide bridges, the interaction
was further studied under reducing conditions. Moreover, we
used a control peptide GGL27 from TFPI-1 (Figure 1D) (35).
We next explored whether EDC34 interacts with the Fab or Fc
part of IgG. To this end the peptide was incubated with the two
fragments. Binding was then assessed by western blot analysis,
showing that only the Fc fragment is able to bind to EDC34,
further underlining the specificity of this interaction (Figure 1E).
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FIGURE 1 | EDC34 binds to immunoglobulins. (A) The antimicrobial activity of EDC34 (6µM) was tested against E. coli bacteria in 10mM Tris, 150mM NaCl, pH 7.4
buffer, containing 20% of serum or citrate or lepirudin or heparin or EDTA plasma. Mean with SD are shown (n = 3). (B) 6µM of EDC34 were incubated in PBS alone
(control) or a buffer containing 20% of serum, citrate, lepirudin, or EDTA plasma for 15 or 30 or 60 or 120min at 37◦C followed by electrophoretic analysis. EDC34
(1 µg) in 10mM Tris was served control. (C) 0.5 µg of EDC34 were incubated with 3 µg of IgG, IgA, IgE, or IgM dissolved in 10mM Tris, 150mM NaCl, pH 7.4 buffer,
for 1 h at 37◦C. (D) EDC34 was incubated with IgG in 1:1 ratio (6µM) at the indicated time points, or pre-incubated for 30min with 50µM of TCEP followed by an
additional 24-h incubation step at 37◦C. GGL27 in the absence of plasma served a control. (E) 6µM of EDC34 were incubated with IgG Fab or Fc fragments (6µM)
for 30min at 37◦C. Samples were separated on SDS-PAGE and probed with an antibody against CAK27 a C-terminal TFPI-2 peptide region.
EDC34-IgG Interaction Is Important to
Boost Complement Activation on Bacterial
Surfaces
To investigate whether EDC34 can alter the antigen-antibody
interactions during infection, human IgGwas pre-incubated with
EDC34 and mixed with E. coli bacteria. Figure 2A shows that
the interaction of EDC34 with human IgG triggered increased
opsonization of immunglobulin on the bacterial surface. This
effect was less pronounced when EDC34 was first preincubated
with E. coli bacteria and then later mixed with human IgG
(Figure 2A). We next tested whether the binding of EDC34
to IgG can promote activation of the classical pathway of
complement. To this end we focused on C1q, as the protein
is part of the first subcomponent of the classical complement
pathway (36). When EDC34 was added to citrate plasma for
1 h we observed a recruitment of C1q to the surface of E. coli
bacteria, which was not seen when plasma alone was incubated
with the bacteria (Figure 2B). This effect was not dependent
on the conditions (reducing or non-reducing) that were chosen.
Together the results show that EDC34 is needed for the assembly
of C1q at the bacterial surface, which is in line with our previous
findings (27). Having shown that EDC34 promotes IgG-mediated
opsonization of C1q at the surface of E. coli bacteria, we next
tested whether this interaction can trigger bactericidal activity.
Figure 3C shows that the incubation of EDC34 with bacteria in
PBS exerts a moderate killing activity, while almost 100% killing
was noted in citrate plasma. Bacterial survival was increased
when immunoglobulin-depleted plasma was used and upon
reconstitution with IgG the depleted plasma retained its full
antimicrobial activity in the presence of peptide (Figures 2C,D).
These results demonstrated the important role of EDC34 in
boosting complement-mediated bacterial killing.
Mapping of the Antimicrobial and
Complement-Activating Site in EDC34
In order tomap the epitope responsible for antimicrobial activity,
the bactericidal effect of EDC34 and shortened versions of the
peptide (Table 1) were tested using E. coli and P. aeruginosa. To
exclude a possible influence of disulphide bonding, a truncated
peptide (AKA27) was employed lacking the first seven amino
acids, including two cysteine residues. Notably, AKA27 consists
of several patches with clustered positively charged amino acids.
Earlier studies have demonstrated these amino acids play an
important role for the antimicrobial activity of many AMPs
(37). To test whether this also applies to AKA27, arginine and
lysine residues of the peptide were sequentially replaced by
a neutral amino acid (serine) as depicted in Table 1. While
AKA27(S1) remained its full antimicrobial potential in 20%
human plasma, the bactericidal activity was decreased when
AKA27(S2) or AKA27(S3) were analyzed under the same
experimental conditions (Figure 3A). To further characterize the
active site, truncated versions of AKA27 were synthesized. The
sequences of these peptides (LKK22, AKA15, and LRF15) as well
as the sequence of a control peptide (DAA14), derived from the
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FIGURE 2 | Interaction of EDC34 with IgG enhances C1q deposition on bacterial surfaces. (A) EDC34 (2µM) was incubated with IgG (8µM) for 24 h in PBS buffer. E.
coli bacteria were for 1 h at 37◦C. Alternatively, EDC34 was incubated with E. coli bacteria and then supplemented with IgG (see also Materials and Methods).
Samples were separated on SDS-PAGE followed by immunoblotting, and probed with anti-IgG antibodies. (B) E. coli bacteria were incubated with citrate plasma
supplemented with 10µM of EDC34 for 1 h at 37◦C. Proteins at the bacterial surface were eluted, concentrated by a pull down assay, and subjected to SDS-PAGE
followed by immunoblotting. Recovered C1q was immuno-detected with anti-C1q antibodies. (C) Using viable count assays, antimicrobial activity of EDC34 against E.
coli was studied. Bacteria and EDC34 were incubated in a PBS buffer, a PBS buffer supplemented with 25 % citrate plasma (CP), a PBS buffer supplemented with
25% immunoglobulin-depleted citrate plasma (DP), or a PBS buffer supplemented with 25% immunoglobulin-depleted citrate plasma reconstituted with IgGs. Mean
with SD are shown (n = 3). (D) Colony cultures of E. coli bacteria grown in the indicated conditions shown in petri dishes.
N-terminal region of TFPI-2, are listed in Table 1. As shown in
Figure 2B, LKK22, spanning the central core region of AKA27,
and LRF15, lacking the N-terminal portion of AKA27, retained
their antimicrobial activity, when incubated with bacteria in the
presence of plasma. However, AKA15, lacking the C-terminal
part of AKA27, and the control peptide (DAA14) had no
antimicrobial activity under these conditions (Figure 3B). The
same activity pattern was recorded using radial diffusion assays
(RDAs). Here the antimicrobial activity of the peptides was tested
under low and high salt conditions. While in the absence of salt
all peptides with the exception DAA14 (negative control) had full
or some antimicrobial activity, only EDC34, AKA27, AKA27(S1),
LKK22, and LRF15 were able impair bacterial growth under high
salt conditions (Figures 3C,D). These findings suggest that the
salt concentration might be in part responsible that AKA27(S2),
AKA27(S3), and AKA15 have lost their antimicrobial activity in
plasma. Finally, we determined the affinity of EDC34, AKA27,
AKA27(S1), AKA27(S2), and AKA27(S3) for human IgG. LL-37
was used as control. SPR analysis were performed by running
the peptides over an IgG coted chip. As depicted in Figure 3E,
EDC34 andAKA27 have highest affinity for IgG, while the affinity
of other peptides showed was significantly lower (Figure 3E).
Together these findings support the notion that the C-terminal
region of AKA27 is important for the interaction with IgG and
subsequent activation of the classical complement pathway.
TFPI-2 Is Highly Expressed During
Infection and Inflammatory Conditions
In order to explore the function of TFPI-2 during systemic
inflammation we analyzed the expression levels of TFPI-2
in two relevant animal models, a murine endotoxin-induced
model and an E. coli infection model. TFPI-2 expression was
investigated in spleen, lung, brain, small, and large intestine,
liver and kidney in challenged/infected or untreated wild type
mice using real-time quantitative PCR (Figure 4A). The results
showed that TFPI-2 mRNA expression was induced by 10-fold
in the spleen already 1 h post-injection of LPS and peaked at
2 h followed by a transient decrease until 12 h post-injection.
The second most effected organ in terms of TFPI-2 expression
was the brain showing a peak of expression 4 h post-injection.
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FIGURE 3 | Mapping of EDC34 epitope. (A,B) C-terminal TFPI-2 derived peptides at indicated concentrations were incubated with E. coli and P. aeruginosa bacteria
in the presence or absence of 20% citrate plasma, and their antimicrobial effects were measured in viable count assays. (C,D) The zone of inhibition of each peptide
(X-axis) against E. coli bacteria was measured in the presence or absence of 150mM NaCl using radial diffusion assays (RDAs). DAA14 was used as a negative
control. Mean with SD is shown (n = 3). (E) Surface plasmon resonance analysis of the interaction between IgG and the indicated peptides in the concentration range
of 25–400 nM is shown.
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FIGURE 4 | TFPI-2 is highly expressed during endotoxin-induced inflammation and sepsis. (A) To measure TFPI-2 expression levels in various organs during
inflammation and systemic bacterial infection TFPI-2+/+ mice were intraperitoneally injected with either 8 mg/kg LPS or E. coli. TFPI-2 mRNA expression levels was
measured at indicated hours post-injection in spleen, lung, brain, kidney, liver, small intestine and large intestine (n = 3). Expression is presented as relative gene
expression levels in relation to housekeeping gene β-actin. The data shown mean ± SEM. (B) Identification of TFPI-2 in COPD patient sputum samples (Lane: 1-4).
Cleavage fragments of TFPI-2 were analyzed by immunoblotting using polyclonal antibodies against C-terminal EDC34 peptide.
The same was found for lungs. In addition, we examined
kidney, large and small intestine and liver which all showed
an additional increase in TFPI-2 expression upon systemic
inflammation induced by LPS from E. coli. The expression
was normalized to time-point 0 h and where expression was
1 time fold change in relation to house- keeping gene β-
actin.
We have previously showed that TFPI-2 is highly expressed
and that C-terminal fragments are present in chronic skin
wounds. In addition to the previous human and current TFPI-
2 expression mouse data, we explored whether C-terminal
fragments of TFPI-2 are present in sputum samples from COPD
patients. Western blot analysis using polyclonal antibodies
against the C-terminal part of TFPI-2 shows that TFPI-2 is
highly expressed and that C-terminal fragments are indeed
associated with immunoglobulins in sputum from a COPD
patient (Figure 4B).
TFPI-2 Is Protective During Systemic
Gram-Negative Infection in vivo
In the last series of experiments, we employed in vivo models
to explore both therapeutic and physiological aspects of our
findings. To this end, we infected mice intraperitoneally with
E. coli bacteria. One hour after the bacterial challenge, mice
were treated with buffer or the mouse-derived TFPI-2 C-terminal
peptide VKG24, a mouse analog of human EDC34. After an
8-h incubation, IVIS R© Spectrum images were taken to detect
ROS production. Mice were then sacrificed and blood, kidney,
lung, liver and spleen were collected to determine bacterial
dissemination. As shown in Figure 5A, ROS production in
VKG24-treated mice was noticeably decreased when compared
with buffer-treated mice. In accordance with these results, we
also noticed that bacterial spreading to the different organs was
reduced in peptide-treated mice when compared to the controls
(Figure 5B).
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FIGURE 5 | Mouse TFPI-2 peptide VKG24 protects mice from E. coli-induced
sepsis. Mice were infected with 100 µl (8–8.5 × 108 cfu/ml) E. coli bacteria.
One hour after infection animals were treated (i. p.) with PBS and VKG24 (500
µg per mouse) for 8 h. Mice (n = 5) were then anesthetized and injected (s. c.)
with L-012 dye to detect ROS production. IVIS® Spectrum with Life Image®
version 4.4 was used for imaging. (A) ROS production in radiance (p/sec) for
control mice (PBS) and mice treated with VKG24 (PBS & VKG24 n = 5).
Representative IVIS® Spectrum images indicating ROS production from two
control (PBS) and treated (VKG24) mice are included. (B) After the IVIS
examination, mice were scarified and organs were harvested for cfu count
measurements (n = 5; liver **p < 0.0048, kidney **p < 0.0036, spleen ****p <
0.0001, ***p < 0.0007, blood ****p < 0.0001).
Given the high expression of TFPI-2 in the lungs during
inflammation, we next wanted to pinpoint the role of TFPI-2
in the respiratory tract. We performed intranasal P. aeruginosa
infection usingTFPI-2−/− andTFPI-2+/+mice.TFPI-2−/−mice
exhibited a significantly lower survival rate compared to wild
type mice (p = 0.003) (Figure 6A). In addition, bacterial load
was measured in both bronchioalveolar lavage fluid (BALF) and
lung tissue was measured after 12 h post-infection (Figure 6B).
Indeed TFPI-2−/− mice exhibited larger amounts of bacteria
in lung tissue compared to wild type mice. Hence, TFPI-2−/−
mice are more prone to P. aeruginosa induced lung infection.
To evaluate if the full-length protein of TFPI-2, in addition
to limit bacterial infiltration, exerts host defense properties by
keeping inflammation at bay during infection we measured
inflammatory cytokine levels in both BALF and citrate plasma
after 12 h post-infection. On a systemic level (plasma) 12 h
post-infection IL-6, IL-10, and MCP-1 was higher in TFPI-
2−/− mice and no significant changes were observed in INF-γ,
TNFα, and IL-12p70 (Figure 6C), whereas in BALF fluid, IL-
10, and MCP-1 was higher in TFPI-2−/− mice. To rule out
the possible anticoagulant activity role of TFPI-2 in TFPI-2−/−
mice, we induced LPS mediated septic shock in TFPI-2+/+
and TFPI-2−/− mice and determined clotting times, platelet
counts and cytokines in whole blood after 6 h post-LPS challenge.
Measurements of clotting times upon endotoxemia did not
reveal any difference between TFPI-2+/+ and TFPI-2−/− mice
(Figure 7A). No significant differences were observed in platelet
counts (Figure 7B), cytokine levels between TFPI-2+/+ and
TFPI-2−/− animals (Figure 7C), indicating that TFPI-2 is not
involved in anticoagulation and inflammation. Together our
results demonstrate a previously undisclosed mechanism based
on boosting of complement-dependent immune response to
infection. A protective role of TFPI-2 was demonstrated during
lung infection by employing TFPI-2−/− and wild type mice.
By using an animal model of infection and treatment with
a C-terminal mouse homolog of EDC34, we found that our
findings can be used for the development of novel antimicrobial
therapies.
DISCUSSION
In this work we present a novel mechanism mediated by
TFPI-2 C-terminal peptides to promote complement mediated
bacterial killing. In addition, using TFPI-2−/− mice we for
the first time show a protective role of TFPI-2 during
Gram-negative infection. Studies using artificial membranes
and live organisms have illustrated that the vast majority
of AMPs exert their antimicrobial activity by permeabilizing
the membrane of the pathogen. Thus a mechanism, leading
to a burst of the bacterial cell wall, has been described
for instance for defensins (38, 39), bactenecins (40), and
magainins (41, 42). However, there are also other mechanisms,
such as the breakage of single-strand DNA by defensins
(43), production of hydrogen peroxide by magainins (44),
or induction of apoptosis by lactoferricin (45) that can
in addition contribute to an elimination of the pathogen.
Based on these findings we hypothesized that EDC34 utilizes
different strategies to exert its antimicrobial activities. This
assumption was based on previous studies showing the
peptide has multifunctional properties, as it not only displays
antimicrobial activity, but it can also activate the classical
complement system and the intrinsic pathway of coagulation
(27, 28).
The complement system is activated by three distinctive
routes, known as the classical, alternative, and lectin pathway,
respectively. Though all three cascades lead to the generation of
the same effector functions, only the classical pathway requires
the opsonization of immunoglobulins at the bacterial surfaces
(46). Recent work has shown that EDC34 can amplify the
classical pathway (28). However, the underlying mechanisms
were not addressed in previous studies. Here we show that
EDC34 exerts its immunomodulatory effect by binding to
immunoglobulins which then helps to augment complement
activation. Though the interaction of C1q with antibodies is
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FIGURE 6 | TFPI-2−/− mice are susceptible to acute Pseudomonas aeruginosa lung infection. (A) Survival. Fifty microliter of P. aeruginosa Xen41 bacteria (3–4 ×
108 cfu/ml) were administered intra-nasally (i.n.) into TFPI-2+/+ and TFPI-2−/− mice. Survival of the mice was monitored every 2 h. The data is pooled from three
different experiments with a total number of 16 wild type mice and 20 TFPI-2−/− mice. (B) BALF and lung tissue was harvested, placed on ice, homogenized (lung
tissue), and colony-forming units (cfu) was determined 12 h after infection (n = 17). (C) Cytokines were analyzed in BALF and plasma (n = 7).
normally needed during this process, it can also occur in
an antibody-independent mechanism. To this end C1q binds
directly to the surface of the pathogen where it triggers structural
changes in the C1s/C1r complex. This then leads to production of
C3a and C3b molecules that play a critical role in inflammation,
bacterial killing, and phagocytosis (46). To initiate classical
pathway C1q has to bind with its CH2 domain to the Fc
region of IgG (47, 48). Our results show that the interaction
of EDC34 with the Fc region of IgG enhances the binding of
immunoglobulin to C1q which then in turn leads to an increased
activation of the classical complement pathway. Notably, the
interaction of EDC34 with the complement system appears
crucial since the endogenous antimicrobial activity of the peptide
was not sufficient for a complete eradication of the invading
pathogen.
TFPI-2 is mainly expressed in brain, spleen and lung
during sepsis and LPS-induced systemic inflammation in mice
(C57BL/6). Surprisingly, TFPI-2−/− mice did not show any
significant impact on coagulation during endotoxin-induced
sepsis. This is contradictory to the previously claimed functional
relevance as an endogenous anti-coagulant, similar to the
highly homologous protein TFPI-1 (49). Platelets are well
established as a cell type that maintains hemostasis and
thrombus growth. Rather than an anti-coagulant, TFPI-2 display
characteristics of a host-defense protein with a possible wide
variety of functions based on it’s expression in the different
organs. Based on the reported data we have for the first
time shown that the TFPI-2 plays a prominent role in
host defense against Gram-negative lung infection in mice.
TFPI-2 could therefore constitute an important acute phase
reactant in lung tissue with bactericidal and immune-regulatory
functions. Based on the detection of proteolytically digested
fragments of TFPI-2 found in sputum from patients with
COPD, our data further implies that proteases can generate
TFPI-2 C-terminal fragments with host defense activities.
Such investigations, along side of monitoring of correlations
to enzymatic activity and clinical outcome, would likely
generate implications for novel treatment routes for COPD
patients.
As a proof of concept from a therapeutic perspective, we
employed an animal model of infection using VKG24, the
murine TFPI-2-derived homolog to EDC34 (27). Previous work
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FIGURE 7 | In vivo TFPI-2 has no significant impact on coagulation. Mice were intraperitoneally injected with either 8 mg/kg LPS, clotting time, platelets and cytokines
were measured after 6 h post-LPS challenge. (A) Clotting times was measured in whole blood. Extrinsic pathway, prothrombin time (PT) and the intrinsic pathway
activated partial thrombin time (aPTT) was determined in TFPI-2+/+ and TFPI-2−/− citrate plasma. (B,C) Total number of platelets counts and indicated cytokine
levels were analyzed in blood from TFPI-2+/+ and TFPI-2−/− mice. No significant differences were observed in between the groups.
has shown that VKG24 exerts, like EDC34, anti-inflammatory
activity and protects mice from fatal LPS shock (50). It was
further reported that VKG24 exhibits antimicrobial killing
activity against E. coli under in vitro conditions (50). Based
on these findings we decided to test the effect of VKG24
in an E. coli sepsis model. Our results show that bacterial
growth was reduced in blood, liver, kidney, spleen, and
lungs when infected mice were treated with VKG24. Along
these lines we also noted that ROS production was notably
lower in these mice, which indicates that VKG24 exerts an
antimicrobial activity by lowering inflammation at the site
of infection. Our current study describes increased cytokine
levels detected in TFPI-2−/− bacterial challenged mice. This
is in line with previously published study where we showed
reduced cytokine levels in LPS challenged mice treated with
VKG24 peptide (50), indicating potent immunomodulatory
activity of C-terminal TFPI-2 region against Gram-negative
infections. In conclusion, our data show that EDC34 possesses
therapeutic potential, as application of the peptide or its murine
homolog not only can kill bacteria by permeabilizing their
membranes, but also by boosting activation of the classical
complement pathway (27). In vivo experiments further reveal
the peptide motif exerts a systemic bacterial killing activity
combined with a non-pathological inflammatory response, which
in combination provides a promising approach for future
therapeutic applications. Taken together, the evidence presented
in this work demonstrates that TFPI-2 is mainly a host-defense
protein, while the anti-coagulative functions likely play a minor
role in normal hemostasis.
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